---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-234722"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:13:14.393399+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10

## Summary
- FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.
- Expansion broadens patient population in Prader-Willi Syndrome; topline data readout expected in Q3 2026.
- CEO cites community support and historical data suggesting younger patients benefit from early intervention.

## SEC filing metadata
- accession: 0001193125-25-234722
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312525234722/0001193125-25-234722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312525234722/ck0001774857-20251008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-234722
- JSON: https://secwatch.observer/filing/0001193125-25-234722.json
- Plain text: https://secwatch.observer/filing/0001193125-25-234722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.